

# Kenneth K Tanabe

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8100499/publications.pdf>

Version: 2024-02-01

146  
papers

8,676  
citations

50170

46  
h-index

48187

88  
g-index

149  
all docs

149  
docs citations

149  
times ranked

12329  
citing authors

#	ARTICLE	IF	CITATIONS
1	Peroxidasin Deficiency Re-programs Macrophages Toward Pro-fibrosis Function and Promotes Collagen Resolution in Liver. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2022, 13, 1483-1509.	2.3	9
2	Abstract 2454: Imaging pancreatic ductal adenocarcinoma using a zinc-sensitive MRI contrast agent: A novel method to detect early-stage PDAC lesions. <i>Cancer Research</i> , 2022, 82, 2454-2454.	0.4	0
3	Abstract 255: Peroxidasin deficiency recruits pro-healing macrophages into the liver and inhibits NAFLD progression to HCC. <i>Cancer Research</i> , 2022, 82, 255-255.	0.4	0
4	Hepatocellular carcinoma chemoprevention by targeting the angiotensin-converting enzyme and EGFR transactivation. <i>JCI Insight</i> , 2022, 7, .	2.3	4
5	Hepatectomy for Solitary Hepatocellular Carcinoma: Resection Margin Width Does Not Predict Survival. <i>Journal of Gastrointestinal Surgery</i> , 2021, 25, 1727-1735.	0.9	9
6	Targeting clinical epigenetic reprogramming for chemoprevention of metabolic and viral hepatocellular carcinoma. <i>Gut</i> , 2021, 70, 157-169.	6.1	57
7	Size of the Largest Colorectal Liver Metastasis Is an Independent Prognostic Factor in the Neoadjuvant Setting. <i>Journal of Surgical Research</i> , 2021, 259, 253-260.	0.8	4
8	Surgical delay and mortality for primary cutaneous melanoma. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 1089-1091.	0.6	8
9	The Clinical Management of Cholangiocarcinoma in the United States and Europe: A Comprehensive and Evidence-Based Comparison of Guidelines. <i>Annals of Surgical Oncology</i> , 2021, 28, 2660-2674.	0.7	38
10	ASO Author Reflections: Variations and Inconsistencies in the Guidelines for the Clinical Management of Cholangiocarcinoma. <i>Annals of Surgical Oncology</i> , 2021, 28, 860-861.	0.7	0
11	Quantitative, noninvasive MRI characterization of disease progression in a mouse model of non-alcoholic steatohepatitis. <i>Scientific Reports</i> , 2021, 11, 6105.	1.6	4
12	Spontaneous Immune-Mediated Regression of Hepatocellular Carcinoma With High Tumor Mutational Burden. <i>JCO Precision Oncology</i> , 2021, 5, 1040-1043.	1.5	2
13	Donâ€™t Let a Crisis Go to Waste. <i>Annals of Surgical Oncology</i> , 2021, 28, 4759-4761.	0.7	0
14	Abstract 1309: HSV1 oncolytic therapy for breast cancer meningeal metastases. , 2021, , .		0
15	Open hepatic resection in the elderly at two tertiary referral centers. <i>American Journal of Surgery</i> , 2021, 222, 594-598.	0.9	1
16	A human liver cell-based system modeling a clinical prognostic liver signature for therapeutic discovery. <i>Nature Communications</i> , 2021, 12, 5525.	5.8	21
17	Molecular Magnetic Resonance Imaging of Liver Fibrosis and Fibrogenesis Is Not Altered by Inflammation. <i>Investigative Radiology</i> , 2021, 56, 244-251.	3.5	6
18	Management implications of fluorodeoxyglucose positron emission tomography/magnetic resonance in untreated intrahepatic cholangiocarcinoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 1871-1884.	3.3	32

#	ARTICLE	IF	CITATIONS
19	Using Smartphones to Capture Novel Recovery Metrics After Cancer Surgery. <i>JAMA Surgery</i> , 2020, 155, 123.	2.2	71
20	Palliative External Beam Radiation Therapy for Hepatocellular Carcinoma With Right Atrial Tumor Thrombus. <i>Practical Radiation Oncology</i> , 2020, 10, e183-e187.	1.1	2
21	Hypofractionated Radiation Therapy for Unresectable/Locally Recurrent Intrahepatic Cholangiocarcinoma. <i>Annals of Surgical Oncology</i> , 2020, 27, 1122-1129.	0.7	29
22	Molecular Magnetic Resonance Imaging of Fibrin Deposition in the Liver as an Indicator of Tissue Injury and Inflammation. <i>Investigative Radiology</i> , 2020, 55, 209-216.	3.5	15
23	Choices of Therapeutic Strategies for Colorectal Liver Metastases Among Expert Liver Surgeons. <i>Annals of Surgery</i> , 2020, 272, 715-722.	2.1	53
24	Risk Factors, Pathogenesis, and Strategies for Hepatocellular Carcinoma Prevention: Emphasis on Secondary Prevention and Its Translational Challenges. <i>Journal of Clinical Medicine</i> , 2020, 9, 3817.	1.0	27
25	Patterns of Failure and the Need for Biliary Intervention in Resected Biliary Tract Cancers After Chemoradiation. <i>Annals of Surgical Oncology</i> , 2020, 27, 5161-5172.	0.7	4
26	Collagen-targeted molecular imaging in diffuse liver diseases. <i>Abdominal Radiology</i> , 2020, 45, 3545-3556.	1.0	7
27	Advanced MRI of Liver Fibrosis and Treatment Response in a Rat Model of Nonalcoholic Steatohepatitis. <i>Radiology</i> , 2020, 296, 67-75.	3.6	22
28	COVID-19 Pandemic and Surgical Oncology: Preserving the Academic Mission. <i>Annals of Surgical Oncology</i> , 2020, 27, 2591-2599.	0.7	12
29	Surgical Oncologists and the COVID-19 Pandemic: Guiding Cancer Patients Effectively through Turbulence and Change. <i>Annals of Surgical Oncology</i> , 2020, 27, 2600-2613.	0.7	31
30	A Shifting Paradigm in Diagnosis and Management of Hepatic Adenoma. <i>Annals of Surgical Oncology</i> , 2020, 27, 3330-3338.	0.7	13
31	ASO Author Reflections: Developing Personalized Care for Hepatocellular Adenoma Based on Subtype Classification. <i>Annals of Surgical Oncology</i> , 2020, 27, 3339-3340.	0.7	0
32	Platelet and neutrophil to lymphocyte ratios predict survival in patients with resectable colorectal liver metastases. <i>American Journal of Surgery</i> , 2020, 220, 1579-1585.	0.9	12
33	Fibrotic Response to Neoadjuvant Therapy Predicts Survival in Pancreatic Cancer and Is Measurable with Collagen-Targeted Molecular MRI. <i>Clinical Cancer Research</i> , 2020, 26, 5007-5018.	3.2	29
34	A Multidisciplinary Team Approach for Triage of Elective Cancer Surgery at the Massachusetts General Hospital During the Novel Coronavirus COVID-19 Outbreak. <i>Annals of Surgery</i> , 2020, 272, e20-e21.	2.1	33
35	Socioeconomic determinants of the surgical treatment of colorectal liver metastases. <i>American Journal of Surgery</i> , 2020, 220, 952-957.	0.9	9
36	Desmoid tumor presenting 2 years after elective Roux-en-Y gastric bypass: a case report and review of the literature. <i>Journal of Surgical Case Reports</i> , 2020, 2020, rjz379.	0.2	2

#	ARTICLE	IF	CITATIONS
37	Epigallocatechin Gallate Induces Hepatic Stellate Cell Senescence and Attenuates Development of Hepatocellular Carcinoma. <i>Cancer Prevention Research</i> , 2020, 13, 497-508.	0.7	24
38	Prevention Strategies for Hepatocellular Carcinoma. <i>Molecular and Translational Medicine</i> , 2019, , 255-289.	0.4	2
39	Facility Type is Associated with Margin Status and Overall Survival of Patients with Resected Intrahepatic Cholangiocarcinoma. <i>Annals of Surgical Oncology</i> , 2019, 26, 4091-4099.	0.7	31
40	Recent Developments and Therapeutic Strategies against Hepatocellular Carcinoma. <i>Cancer Research</i> , 2019, 79, 4326-4330.	0.4	99
41	ASO Author Reflections: A New Look at the Clinical Significance of MVI in Hepatocellular Carcinoma. <i>Annals of Surgical Oncology</i> , 2019, 26, 617-618.	0.7	0
42	TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion-Positive Intrahepatic Cholangiocarcinoma. <i>Cancer Discovery</i> , 2019, 9, 1064-1079.	7.7	254
43	Predictors of adjuvant treatment and survival in patients with intrahepatic cholangiocarcinoma who undergo resection. <i>American Journal of Surgery</i> , 2019, 218, 959-966.	0.9	14
44	Protons versus Photons for Unresectable Hepatocellular Carcinoma: Liver Decompensation and Overall Survival. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, 64-72.	0.4	99
45	Molecular Magnetic Resonance Imaging Using a Redox-Active Iron Complex. <i>Journal of the American Chemical Society</i> , 2019, 141, 5916-5925.	6.6	96
46	Prognostic and Therapeutic Implications of Microvascular Invasion in Hepatocellular Carcinoma. <i>Annals of Surgical Oncology</i> , 2019, 26, 1474-1493.	0.7	255
47	Tumor Contrast Enhancement and Whole-Body Elimination of the Manganese-Based Magnetic Resonance Imaging Contrast Agent Mn-PyC3A. <i>Investigative Radiology</i> , 2019, 54, 697-703.	3.5	45
48	Inhibition of Acetyl-CoA Carboxylase by Phosphorylation or the Inhibitor ND-654 Suppresses Lipogenesis and Hepatocellular Carcinoma. <i>Cell Metabolism</i> , 2019, 29, 174-182.e5.	7.2	246
49	Hepatocellular Carcinoma in Transplantable Child-Pugh A Cirrhotics: Should Cost Affect Resection vs Transplantation?. <i>Journal of Gastrointestinal Surgery</i> , 2019, 23, 1135-1142.	0.9	6
50	A model of breast cancer meningeal metastases: characterization with in vivo molecular imaging. <i>Cancer Gene Therapy</i> , 2019, 26, 145-156.	2.2	5
51	Surgical resection versus ablation for early-stage hepatocellular carcinoma: A retrospective cohort analysis. <i>American Journal of Surgery</i> , 2019, 218, 157-163.	0.9	13
52	Pioglitazone Reduces Hepatocellular Carcinoma Development in Two Rodent Models of Cirrhosis. <i>Journal of Gastrointestinal Surgery</i> , 2019, 23, 101-111.	0.9	30
53	Hypofractionated radiation therapy for unresectable/locally recurrent intrahepatic cholangiocarcinoma.. <i>Journal of Clinical Oncology</i> , 2019, 37, 412-412.	0.8	1
54	Cutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 367-402.	2.3	326

#	ARTICLE	IF	CITATIONS
55	Molecular signatures in hepatocellular carcinoma: A step toward rationally designed cancer therapy. <i>Cancer</i> , 2018, 124, 3084-3104.	2.0	42
56	Liver reirradiation for patients with hepatocellular carcinoma and liver metastasis. <i>Practical Radiation Oncology</i> , 2018, 8, 414-421.	1.1	17
57	Molecular magnetic resonance imaging accurately measures the antifibrotic effect of EDP-305, a novel farnesoid X receptor agonist. <i>Hepatology Communications</i> , 2018, 2, 821-835.	2.0	46
58	Orthotopic and heterotopic murine models of pancreatic cancer and their different responses to FOLFIRINOX chemotherapy. <i>DMM Disease Models and Mechanisms</i> , 2018, 11, .	1.2	60
59	CM-101: Type I Collagen-targeted MR Imaging Probe for Detection of Liver Fibrosis. <i>Radiology</i> , 2018, 287, 581-589.	3.6	43
60	Feasibility of Ultra-High-Throughput Functional Screening of Melanoma Biopsies for Discovery of Novel Cancer Drug Combinations. <i>Clinical Cancer Research</i> , 2017, 23, 4680-4692.	3.2	8
61	Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	3.0	82
62	Tricyclic Antidepressants Promote Ceramide Accumulation to Regulate Collagen Production in Human Hepatic Stellate Cells. <i>Scientific Reports</i> , 2017, 7, 44867.	1.6	22
63	A novel chemoradiation targeting stem and nonstem pancreatic cancer cells by repurposing disulfiram. <i>Cancer Letters</i> , 2017, 409, 9-19.	3.2	48
64	Prognostic Significance of Surgical Margin Size After Neoadjuvant FOLFOX and/or FOLFIRI for Colorectal Liver Metastases. <i>Journal of Gastrointestinal Surgery</i> , 2017, 21, 1831-1840.	0.9	14
65	Combined magnetic resonance elastography and collagen molecular magnetic resonance imaging accurately stage liver fibrosis in a rat model. <i>Hepatology</i> , 2017, 65, 1015-1025.	3.6	43
66	Hepatocellular carcinoma: early-stage management challenges. <i>Journal of Hepatocellular Carcinoma</i> , 2017, Volume 4, 81-92.	1.8	60
67	Molecular imaging of oxidized collagen quantifies pulmonary and hepatic fibrogenesis. <i>JCI Insight</i> , 2017, 2, .	2.3	57
68	STAT3 is a key transcriptional regulator of cancer stem cell marker CD133 in HCC. <i>Hepatobiliary Surgery and Nutrition</i> , 2016, 5, 201-203.	0.7	23
69	Metformin prevents hepatocellular carcinoma development by suppressing hepatic progenitor cell activation in a rat model of cirrhosis. <i>Cancer</i> , 2016, 122, 1216-1227.	2.0	65
70	Impact of <i>EGF</i> , <i>IL28B</i> , and <i>PNPLA3</i> polymorphisms on the outcome of allograft hepatitis C: a multicenter study. <i>Clinical Transplantation</i> , 2016, 30, 452-460.	0.8	2
71	Molecular Liver Cancer Prevention in Cirrhosis by Organ Transcriptome Analysis and Lysophosphatidic Acid Pathway Inhibition. <i>Cancer Cell</i> , 2016, 30, 879-890.	7.7	172
72	What's New in Gastric and Esophageal Cancers. <i>Annals of Surgical Oncology</i> , 2016, 23, 3773-3773.	0.7	0

#	ARTICLE	IF	CITATIONS
73	Multi-Institutional Phase II Study of High-Dose Hypofractionated Proton Beam Therapy in Patients With Localized, Unresectable Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. <i>Journal of Clinical Oncology</i> , 2016, 34, 460-468.	0.8	363
74	PD-L1 and HLA Class I Antigen Expression and Clinical Course of the Disease in Intrahepatic Cholangiocarcinoma. <i>Clinical Cancer Research</i> , 2016, 22, 470-478.	3.2	168
75	T2 relaxation time is related to liver fibrosis severity. <i>Quantitative Imaging in Medicine and Surgery</i> , 2016, 6, 103-114.	1.1	54
76	A multi-institutional phase II study of high-dose hypofractionated proton beam therapy (HF-PBT) for unresectable primary liver cancers: Long-term outcomes in patients (pts) with hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 376-376.	0.8	2
77	Reply. <i>Hepatology</i> , 2015, 61, 729-730.	3.6	0
78	Are We Thinking? A Commentary on "Partial-ALPPS Safer Than ALPPS? A Single-center Experience". <i>Annals of Surgery</i> , 2015, 261, e93.	2.1	2
79	<i>CD44</i> single nucleotide polymorphism and isoform switching may predict gastric cancer recurrence. <i>Journal of Surgical Oncology</i> , 2015, 112, 622-628.	0.8	14
80	Clinical Significance of Microscopic Melanoma Metastases in the Nonhottest Sentinel Lymph Nodes. <i>JAMA Surgery</i> , 2015, 150, 465.	2.2	9
81	Assessment of Proliferation and Cytotoxicity in a Biomimetic Three-Dimensional Model of Lung Cancer. <i>Annals of Thoracic Surgery</i> , 2015, 100, 414-421.	0.7	25
82	Prognosis and Clinicopathologic Features of Patients With Advanced Stage Isocitrate Dehydrogenase (IDH) Mutant and IDH Wild-Type Intrahepatic Cholangiocarcinoma. <i>Oncologist</i> , 2015, 20, 1019-1027.	1.9	112
83	3D molecular MR imaging of liver fibrosis and response to rapamycin therapy in a bile duct ligation rat model. <i>Journal of Hepatology</i> , 2015, 63, 689-696.	1.8	57
84	Commentary on "Can we improve the morbidity and mortality associated with the associating liver partition with portal vein ligation for staged hepatectomy (ALPPS) procedure in the management of colorectal liver metastases?". <i>Surgery</i> , 2015, 157, 204-206.	1.0	6
85	Outcome of patients with de novo versus nevus-associated melanoma. <i>Journal of the American Academy of Dermatology</i> , 2015, 72, 54-58.	0.6	71
86	Multi-institutional phase II study of high dose, hypofractionated proton beam therapy (HF-PBT) for unresectable primary liver cancers: Long term outcomes in patients (pts) with intrahepatic cholangiocarcinoma (ICC).. <i>Journal of Clinical Oncology</i> , 2015, 33, 4020-4020.	0.8	2
87	Epidermal growth factor receptor inhibition attenuates liver fibrosis and development of hepatocellular carcinoma. <i>Hepatology</i> , 2014, 59, 1577-1590.	3.6	290
88	A prospective feasibility study of respiratory-gated proton beam therapy for liver tumors. <i>Practical Radiation Oncology</i> , 2014, 4, 316-322.	1.1	42
89	Approaches to Regional Nodes in Patients With Melanoma. <i>Journal of Clinical Oncology</i> , 2014, 32, 881-885.	0.8	4
90	Molecular Imaging with Bioluminescence and PET Reveals Viral Oncolysis Kinetics and Tumor Viability. <i>Cancer Research</i> , 2014, 74, 4111-4121.	0.4	11

#	ARTICLE	IF	CITATIONS
91	The clinical management of hepatocellular carcinoma in the United States, Europe, and Asia: A comprehensive and evidence-based comparison and review. <i>Cancer</i> , 2014, 120, 2824-2838.	2.0	212
92	Variability in immune infiltrates and HLA expression in cholangiocarcinoma. <i>Journal of Clinical Oncology</i> , 2014, 32, 230-230.	0.8	2
93	Host Genetics Predict Clinical Deterioration in HCV-Related Cirrhosis. <i>PLoS ONE</i> , 2014, 9, e114747.	1.1	11
94	Prognostic Gene Signatures for Hepatocellular Carcinoma: What Are We Measuring?. <i>Annals of Surgical Oncology</i> , 2013, 20, 3707-3708.	0.7	1
95	Molecular MRI of collagen to diagnose and stage liver fibrosis. <i>Journal of Hepatology</i> , 2013, 59, 992-998.	1.8	128
96	Optimism for Treatment of Hepatocellular Carcinoma. <i>Molecular Therapy</i> , 2013, 21, 722-724.	3.7	4
97	Melanoma, Version 2.2013. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013, 11, 395-407.	2.3	134
98	A functional polymorphism in the epidermal growth factor gene predicts hepatocellular carcinoma risk in Japanese hepatitis C patients. <i>OncoTargets and Therapy</i> , 2013, 6, 1805.	1.0	18
99	Quantitative characterization of hepatocellular carcinoma and metastatic liver tumor by CT perfusion. <i>Cancer Imaging</i> , 2013, 13, 512-519.	1.2	15
100	Circulating oncometabolite 2-hydroxyglutarate (2HG) as a potential surrogate biomarker in patients with isocitrate dehydrogenase mutant (IDHm) intrahepatic cholangiocarcinoma (ICC). <i>Journal of Clinical Oncology</i> , 2013, 31, 4125-4125.	0.8	0
101	Angiogenesis Inhibition Using an Oncolytic Herpes Simplex Virus Expressing Endostatin in a Murine Lung Cancer Model. <i>Cancer Investigation</i> , 2012, 30, 243-250.	0.6	19
102	Frequent Mutation of Isocitrate Dehydrogenase (IDH1) and IDH2 in Cholangiocarcinoma Identified Through Broad-Based Tumor Genotyping. <i>Oncologist</i> , 2012, 17, 72-79.	1.9	629
103	Melanoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2012, 10, 366-400.	2.3	63
104	Genomic risk of hepatitis C-related hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2012, 56, 729-730.	1.8	15
105	Molecular MR imaging of liver fibrosis: A feasibility study using rat and mouse models. <i>Journal of Hepatology</i> , 2012, 57, 549-555.	1.8	97
106	Patient Selection, Resection, and Outcomes for Hepatocellular Carcinoma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2012, , 265-269.	1.8	0
107	Prevention of hepatocellular carcinoma: potential targets, experimental models, and clinical challenges. <i>Current Cancer Drug Targets</i> , 2012, 12, 1129-59.	0.8	55
108	A Functional Polymorphism in the Epidermal Growth Factor Gene Is Associated With Risk for Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2011, 141, 141-149.	0.6	133

#	ARTICLE	IF	CITATIONS
109	Clinical Value of Radiographic Staging in Patients Diagnosed With AJCC Stage III Melanoma. <i>Annals of Surgical Oncology</i> , 2011, 18, 506-513.	0.7	18
110	Creating and Providing Predictions of Melanoma Outcome. <i>Annals of Surgical Oncology</i> , 2010, 17, 1981-1982.	0.7	3
111	Mouse model of carbon tetrachloride induced liver fibrosis: Histopathological changes and expression of CD133 and epidermal growth factor. <i>BMC Gastroenterology</i> , 2010, 10, 79.	0.8	151
112	New Trends and Novel Treatment for Hepatocellular Carcinoma: A Global Perspective. <i>Oncologist</i> , 2010, 15, 1-4.	1.9	9
113	Case 30-2010. <i>New England Journal of Medicine</i> , 2010, 363, 1352-1360.	13.9	0
114	Why cancer at the primary site and in the lymph nodes contributes to the risk of cancer death. <i>Cancer</i> , 2009, 115, 5084-5094.	2.0	23
115	The impact of primary tumor size, lymph node status, and other prognostic factors on the risk of cancer death. <i>Cancer</i> , 2009, 115, 5071-5083.	2.0	55
116	How cancer at the primary site and in the lymph nodes contributes to the risk of cancer death. <i>Cancer</i> , 2009, 115, 5095-5107.	2.0	21
117	Melanoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2009, 7, 250-275.	2.3	120
118	The past 60 years in liver surgery. <i>Cancer</i> , 2008, 113, 1888-1896.	2.0	14
119	A Functional Epidermal Growth Factor (EGF) Polymorphism, EGF Serum Levels, and Esophageal Adenocarcinoma Risk and Outcome. <i>Clinical Cancer Research</i> , 2008, 14, 3216-3222.	3.2	80
120	Epithelial-to-Mesenchymal Transition and Integrin-Linked Kinase Mediate Sensitivity to Epidermal Growth Factor Receptor Inhibition in Human Hepatoma Cells. <i>Cancer Research</i> , 2008, 68, 2391-2399.	0.4	287
121	Epidermal Growth Factor Gene Functional Polymorphism and the Risk of Hepatocellular Carcinoma in Patients With Cirrhosis. <i>JAMA - Journal of the American Medical Association</i> , 2008, 299, 53-60.	3.8	183
122	Positron Emission Tomography of Herpes Simplex Virus 1 Oncolysis. <i>Cancer Research</i> , 2007, 67, 3295-3300.	0.4	35
123	HSV-1 Viral Oncolysis and Molecular Imaging with PET. <i>Current Cancer Drug Targets</i> , 2007, 7, 175-180.	0.8	10
124	Melanoma in the young: Differences and similarities with adult melanoma. <i>Cancer</i> , 2007, 110, 614-624.	2.0	144
125	Morbidity and Mortality after Liver Resection: Results of the Patient Safety in Surgery Study. <i>Journal of the American College of Surgeons</i> , 2007, 204, 1284-1292.	0.2	207
126	Should Surgical Resection Be Combined with Imatinib Therapy for Locally Advanced or Metastatic Gastrointestinal Stromal Tumors?. <i>Annals of Surgical Oncology</i> , 2007, 14, 1784-1786.	0.7	4



#	ARTICLE	IF	CITATIONS
127	Emerging therapies for metastatic carcinoma to the liver. <i>Community Oncology</i> , 2006, 3, 567-573.	0.2	2
128	New Techniques of Liver Surgery. <i>Seminars in Oncology</i> , 2006, 33, 39-41.	0.8	3
129	Viral oncolysis by herpes simplex virus and other viruses. <i>Cancer Biology and Therapy</i> , 2005, 4, 524-531.	1.5	36
130	Case 23-2005. <i>New England Journal of Medicine</i> , 2005, 353, 401-410.	13.9	2
131	Radiofrequency ablation. <i>Cancer</i> , 2004, 100, 641-650.	2.0	72
132	Oncolysis by viral replication and inhibition of angiogenesis by a replication-conditional herpes simplex virus that expresses mouse endostatin. <i>Cancer</i> , 2004, 101, 869-877.	2.0	36
133	Viral Oncolysis. <i>Oncologist</i> , 2002, 7, 106-119.	1.9	122
134	Prodrug bioactivation and oncolysis of diffuse liver metastases by a herpes simplex virus 1 mutant that expresses the CYP2B1 transgene. <i>Cancer</i> , 2002, 95, 1171-1181.	2.0	73
135	CD44s expression in human colon carcinomas influences growth of liver metastases. , 2000, 85, 523-526.		48
136	Treatment of intrahepatic malignancy with radiofrequency ablation. <i>Cancer</i> , 2000, 88, 2452-2463.	2.0	583
137	An oncolytic herpes simplex virus type 1 selectively destroys diffuse liver metastases from colon carcinoma. <i>FASEB Journal</i> , 2000, 14, 301-311.	0.2	107
138	CD44s expression in human colon carcinomas influences growth of liver metastases. , 2000, 85, 523.		1
139	Treatment of intrahepatic malignancy with radiofrequency ablation. <i>Cancer</i> , 2000, 88, 2452-2463.	2.0	17
140	Detection of microscopic melanoma metastases in sentinel lymph nodes. , 1999, 86, 617-627.		192
141	Involvement of CD44 in matrix metalloproteinase-2 regulation in human melanoma cells. , 1999, 80, 387-395.		70
142	Ephemeral Seeds: Microembolization of Tumor Cells During Surgery. <i>Annals of Surgical Oncology</i> , 1999, 6, 631-632.	0.7	1
143	Detection of microscopic melanoma metastases in sentinel lymph nodes. , 1999, 86, 617.		2
144	Surgical Treatment and Other Regional Treatments for Colorectal Cancer Liver Metastases. <i>Oncologist</i> , 1999, 4, 197-208.	1.9	104

#	ARTICLE	IF	CITATIONS
145	Cancer Gene Therapy Using a Replication-Competent Herpes Simplex Virus Type 1 Vector. <i>Annals of Surgery</i> , 1998, 228, 366-374.	2.1	73
146	Enhancement of Gene Therapy Specificity for Diffuse Colon Carcinoma Liver Metastases with Recombinant Herpes Simplex Virus. <i>Annals of Surgery</i> , 1996, 224, 323-330.	2.1	83